Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review

Authors

• Gaurav Nepal, Department of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, Nepal.
• Mahika Khurana, Department of Public Health, Berkeley Public Health Division, Berkeley, CA 94704, USA.
• Domenica Herrera Bucheli, Department of Medicine, Universidad Internacional de Ecuador, Loja 110150, Ecuador.
• Siddhartha Bhandari, Department of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, Nepal.
• Utsav Joshi, Rochester Regional HealthFollow
• Riwaj Bhagat, Department of Neurology, Boston University Medical Center, Boston, MA 02118, USA.
• Jessica Holly Rehrig, Department of Neurology, North Shore University Hospital, Manhasset, NY 11030, USA.
• Prasun Pudasainee, Department of Internal Medicine, AMITA Health Saint Francis Hospital, Evanston, IL 60202, USA.
• Yow Ka Shing, Department of Internal Medicine, National University Hospital, Singapore 119074, Singapore.
• Juan Fernando Ortiz, Department of Neurology, California Institute of Behavioral Neuroscience & Psychology, Fairfield, CA 94534, USA.
• Rajeev Ojha, Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, Nepal.
• Bikram Prasad Gajurel, Department of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, Nepal.
• Jonathan Quinonez, Department of Neurology, Larkin Community Hospital, South Miami, FL 100181, USA.
• Samir Ruxmohan, Department of Neurology, Larkin Community Hospital, South Miami, FL 100181, USA.
• Trevine Albert, Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA.
• Steven Licata, Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA.
• Joel Stien, Department of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USA.

Department

Internal Medicine

Document Type

Article

Publication Title

Neurology International

Abstract

Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1-2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.

First Page

99

Last Page

108

DOI

10.3390/neurolint14010009

Volume

14

Issue

1

Publication Date

1-11-2022

PubMed ID

35076567

Recommended Citation

Nepal, G., Khurana, M., Bucheli, D. H., Bhandari, S., Joshi, U., Bhagat, R., Rehrig, J. H., Pudasainee, P., Shing, Y. K., Ortiz, J. F., Ojha, R., Gajurel, B. P., Quinonez, J., Ruxmohan, S., Albert, T., Licata, S., & Stien, J. (2022). Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International, 14 (1), 99-108. https://doi.org/10.3390/neurolint14010009